Fundraising FoxJenaValve
Irvine, US · 20 known investors
Find your way into JenaValve
Sign up to see every warm intro you have to JenaValve
- Paths you didn't know you had: your email and LinkedIn already hold routes to the JenaValve team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
JenaValve develops transcatheter aortic valve replacement systems to treat severe aortic regurgitation and aortic stenosis. The company's products are designed for interventional cardiology clinicians treating patients with structural heart disease.
Founders & leadership
HF.jpg)
Hans FigullaCo-founder
MF
Markus Ferrari
VC
Victoria Carr-BrendelExecutive
DD
David DrachmanExecutive
Board
AK
EA
Erik AmbleBoard director
PB
Peter BarrettBoard director
OL
OX
Ouyang XiangyuBoard director
PV
Patrick van BenedenBoard director
RC
Investors · 20
Andera Partnerslisted by Andera PartnersParis
How we know: Andera Partners's portfolio page · a partner's Signal profile · globenewswire.com · Not right? Tell us
Bain Capital Life Scienceslisted by Bain Capital Life SciencesBostonvia Andrew Hack · board
How we know: Bain Capital Life Sciences's portfolio page · board seat on SEC Form D · globenewswire.com · Not right? Tell us
Rosetta Capital Ltd.listed by Rosetta Capital Ltd.Oxford
How we know: Rosetta Capital Ltd.'s portfolio page · Not right? Tell us
VI Partnerslisted by VI PartnersAltendorf · $2.2M – $4.5Mvia Arnd Kaltofen · board
How we know: VI Partners's portfolio page · board seat on SEC Form D · prnewswire.com · Not right? Tell us
Atlas VenturereportedCambridge · $500K – $1M
How we know: a partner's Signal profile · Not right? Tell us
Legend CapitalreportedBeijing · $2M – $10M
How we know: funding news · prnewswire.com · Not right? Tell us
Neomed Managementreported
How we know: prnewswire.com · Not right? Tell us
Omega FundsreportedBoston
How we know: prnewswire.com · Not right? Tell us
Also in the syndicate · 8
Atlas Venture FundCormorant Asset ManagementEdmond de Rothschild Investment PartnersPeijia Medical LimitedPictet Alternative Advisors SARMMValiance AdvisorsVenture Incubator
Reported raises · per SEC filings
Form D private placements$315M disclosed across 8 rounds · 2013–2021
▶$100.4MraisedApr 2024 · 17 investors · Other Health CareRule 506(b)
▶$100.4MraisedApr 2024 · 17 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Daniel DearenDirector
- Jan KeltjensDirector
- John KilcoyneExecutive Officer, Director
- Andrew HackDirector
- Jan PensaertDirector
- Keith DawkinsDirector
- Olivier LitzkaDirector
- Kenneth MacLeodDirector
- Offering amount
- $100.4M
- Amount sold
- $100.4M
- Sales commissions
- $525K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$66.5MraisedOct 2020 · 8 investors · Other Health CareRule 506(b)
▶$66.5MraisedOct 2020 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Andrew HackDirector
- Olivier LitzkaDirector
- Erik AmbleDirector
- Patrick van BenedenDirector
- Jose (Pepe) Calle GordoDirector
- Rudi MarienDirector
- Peter WulffExecutive Officer
- John KilcoyneExecutive Officer, Director
- Jan KeltjensDirector
- Keith DawkinsDirector
- Offering amount
- $66.5M
- Amount sold
- $66.5M
- Finders' fees
- $1.6M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.5MraisedJun 2019 · 10 investors · Other Health CareRule 506(b)
▶$14.5MraisedJun 2019 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John KilcoyneExecutive Officer, Director
- Jose Calle GordoDirector
- Peter WulffExecutive Officer
- Jan PensaertDirector
- Jan KeltjensDirector
- Keith DawkinsDirector
- Olivier LitzkaDirector
- Rudi MarienDirector
- Erik AmbleDirector
- Patrick van BenedenDirector
- Offering amount
- $14.5M
- Amount sold
- $14.5M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.3MraisedJul 2018 · 11 investors · Other TechnologyRule 506(b)
▶$14.3MraisedJul 2018 · 11 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Olivier LitzkaDirector
- Patrick van BenedenDirector
- Jan PensaertDirector
- Rudi MarienDirector
- Jose (Pepe) Calle GordoDirector
- Keith DawkinsDirector
- Victoria Carr-BrendelExecutive Officer
- Quan ZhouDirector
- Erik AmbleDirector
- Jan KeltjensDirector
- Offering amount
- $14.3M
- Amount sold
- $14.3M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.4MraisedAug 2017 · 14 investors · Other Health CareRule 506(b)
▶$9.4MraisedAug 2017 · 14 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ouyang XiangyuDirector
- Robert MitchellDirector
- Patrick van BenedenDirector
- Erik AmbleDirector
- Olivier LitzkaDirector
- Victoria Carr-BrendelExecutive Officer, Director
- Jan PensaertDirector
- Jan KeltjensDirector
- Peter WulffExecutive Officer
- Arnd KaltofenDirector
- Offering amount
- $9.4M
- Amount sold
- $9.4M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedAug 2016 · 11 investors · Other Health CareRule 506(b)
▶$10MraisedAug 2016 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jan PensaertDirector
- Raymond CohenDirector
- Peter WulffExecutive Officer
- Arnd KaltofenDirector
- Jan KeltjensDirector
- Patrick van BenedenDirector
- Ouyang XiangyuDirector
- Victoria Carr-BrendelExecutive Officer, Director
- Erik AmbleDirector
- Olivier LitzkaDirector
- Offering amount
- $23M
- Amount sold
- $10M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$26.5MraisedAug 2015 · 13 investors · Other Health CareRule 506(b)
▶$26.5MraisedAug 2015 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Arnd KaltofenDirector
- Raymond CohenDirector
- Erik AmbleDirector
- Jan KeltjensDirector
- Peter BarrettDirector
- Olivier LitzkaDirector
- Ouyang XiangyuDirector
- Patrick van BenedenDirector
- Victoria Carr-BrendelExecutive Officer, Director
- Hans-Reiner FigullaDirector
- Offering amount
- $26.5M
- Amount sold
- $26.5M
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$73.4MraisedNov 2014 · 15 investors · Other Health CareRule 506(b)
▶$73.4MraisedNov 2014 · 15 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Erik AmbleDirector
- Patrick van BenedenDirector
- Ouyang XiangyuDirector
- Raymond CohenDirector
- Peter BarrettDirector
- Arnd KaltofenDirector
- Hans-Reiner FigullaDirector
- Jan KeltjensDirector
- David DrachmanExecutive Officer, Director
- Olivier LitzkaDirector
- Offering amount
- $73.4M
- Amount sold
- $73.4M
- First sale
- Jul 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Edwards LifesciencesEdwards Lifesciences develops innovative medical technologies for treating cardiovascular disease, focusing on structural heart interventions. The company serves patients and healthcare providers globally through partnerships with clinicians and healthcare stakeholders.
PowerPower builds a patient-friendly platform to discover and enroll in clinical trials, serving patients seeking access to research studies and researchers seeking to improve patient recruitment. The company operates in the healthcare technology and clinical research industry.
Boston ScientificBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Companies working in the same space as JenaValve.
In the news
Frequently asked questions
- What does JenaValve do?
- JenaValve develops transcatheter aortic valve replacement systems to treat severe aortic regurgitation and aortic stenosis. The company's products are designed for interventional cardiology clinicians treating patients with structural heart disease.
- Who founded JenaValve?
- JenaValve was founded by Hans Figulla, Markus Ferrari.
- Who are JenaValve's investors?
- JenaValve's investors include Andera Partners, Bain Capital Life Sciences, Rosetta Capital Ltd., VI Partners, Atlas Venture, Gimv, Innovatus Capital Partners, Legend Capital and 4 more.
- How much funding has JenaValve raised?
- JenaValve has disclosed $315M raised across 8 rounds.
- Where is JenaValve headquartered?
- JenaValve is headquartered in Irvine, US.